RNXT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.1M
+17.3%
909.0K
+61.5%
563.0K
+136.6%
238.0K
-10.5%
266.0K
Cost of Revenue
188.0K
+31.5%
143.0K
+70.2%
84.0K
+200.0%
28.0K
-47.2%
53.0K
Gross Profit
878.0K
+14.6%
766.0K
+59.9%
479.0K
+128.1%
210.0K
-1.4%
213.0K
Operating Expenses
4.1M
-0.0%
4.1M
+4.2%
3.9M
+5.8%
3.7M
+9.3%
3.4M
R&D
1.2M
+3.4%
1.2M
-2.3%
1.2M
-18.2%
1.5M
-10.9%
1.7M
SG&A
2.9M
-1.4%
2.9M
+7.2%
2.7M
+21.9%
2.2M
+29.1%
1.7M
Operating Income
-3236000
+3.4%
-3349000
+3.5%
-3469000
+1.5%
-3522000
-10.1%
-3200000
EBITDA
-3231000
+3.4%
-3344000
+3.6%
-3468000
+1.5%
-3521000
-10.0%
-3201000
Net Income
-3647000
-25.3%
-2911000
+17.3%
-3521000
-19.7%
-2941000
-1.0%
-2912000
EPS (Basic)
$-0.08
-33.3%
$-0.06
+33.3%
$-0.09
-12.5%
$-0.08
+0.0%
$-0.08
EPS (Diluted)
$-0.08
-33.3%
$-0.06
+33.3%
$-0.09
-12.5%
$-0.08
+0.0%
$-0.08
Shares (Diluted)
48.2M
+1.9%
47.3M
+24.4%
38.0M
+3.6%
36.7M
+0.2%
36.6M
RenovoRx (RNXT) — Financials